Drug Trial Radar · NCT03403712
A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer
Last checked: Nov 20, 2026Latest source record: Jun 1, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
404
Actual
Start
Mar 16, 2018
Primary completion
Sep 19, 2018
Study completion Sep 19, 2018
Sponsor
- Lead sponsor
- Helsinn Healthcare SAIndustry
- Sponsor type
- Industry
- Collaborators
- Emerald Clinical Inc.; The Physicians' Services Incorporated Foundation
- First posted
- Jan 19, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multicenter, randomized, double-blind, double-dummy, parallel group, stratified study assessing the safety and describing the efficacy of a single dose of intravenous (IV) fosnetupitant/palonosetron (260 mg/0.25 mg) infusion \[test\] versus oral netupitant/palonosetron (300 mg/0.5 mg) combination \[control\]; each administered with oral dexamethasone prior to initial and repeated cycles of AC chemotherapy in female breast cancer patients.
Conditions
- Chemotherapy-induced Nausea and Vomiting
Interventions
fosnetupitant/ palonosetronDrug
intravenous fosnetupitant/ palonosetron (260 mg/0.25 mg) fixed-dose combination
netupitant/palonosetronDrug
oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination
dexamethasoneDrug
Oral dexamethasone (12 mg)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent AEs at Cycle 1Time frame: At the end of Cycle 1 (each cycle is 21 days)
- Number of Participants With Treatment-emergent AEs All CyclesTime frame: At the end of Cycle 4 (each cycle is 21 days)
- Number of Participants With Severe (i.e., CTCAE Grade ≥3) TEAEs Reported for ≥2% of Patients in Either Treatment Group and Overall Throughout the StudyTime frame: At the end of Cycle 4 (each cycle is 21 days)
- Number of Participants With Study-Drug-Related TEAEs Reported for ≥2% of Patients in Either Treatment Group Throughout the StudyTime frame: At the end of Cycle 4 (each cycle is 21 days)
Locations
40 sites in 2 countries. Site status is shown where the registry gives one.
The Oncology Inst. Of Hope and Innovation
Tucson, Arizona
Carti Cancer Center
Little Rock, Arkansas
Pacific Cancer Medical Center, Inc.
Anaheim, California
CBCC Global Research, INC at Comprehensive Blood and Cancer Center
Bakersfield, California
The Oncology Tnstitute of Hope and Innovation
Corona, California
Uptimum Medical Group Inc.
Inglewood, California
The Oncology Institute of Hope and Innnovation
Long Beach, California
Hao Wei Zhang M.D.
Los Angeles, California
Emad Ibrahim, MD, INC.
Redlands, California
Watson Clinic LLP
Lakeland, Florida
Mid Florida Hematology and Oncology Center
Orange City, Florida
University Cancer & Blood Center, LLC
Athens, Georgia
Cancer Center of !\!Iiddle Georgia
Dublin, Georgia
Harbin Clinic
Rome, Georgia
Summit Cancer Care
Savannah, Georgia
Edward H. Kaplan MD & Associates
Skokie, Illinois
Presence Infusion Care - Skokie
Skokie, Illinois
Fort Wayne Medical Oncology and Hematology, Inc.
Fort Wayne, Indiana
TU Health Arnett Cancer Center
Lafayette, Indiana
Baptist Health Cancer Center
New Albany, Indiana
Cotton O'Neil Clinical Res. Ctr., Hematology & Oncology
Topeka, Kansas
Cancer Center of Kansas
Wichita, Kansas
Ashland-Bellefonte Cancer Center
Ashland, Kentucky
CHRISTUS Cancer Treatment Center
Shreveport, Louisiana
Mercy Medical Center, Medical Oncology and Hematology
Baltimore, Maryland
Hattiesburg Clinic Hematology Oncology
Hattiesburg, Mississippi
Cornell-Beshore Cancer Institute
Joplin, Missouri
Cox Mcdical ·Centers
Springfield, Missouri
Trinitas Cancer Center
Elizabeth, New Jersey
San Juan Oncology Associates
Farmington, New Mexico
Mid Ohio Oncology/Hematology Inc. DBA The Mark H. Zangmeister Center
Columbus, Ohio
Toledo Clinic Cancer Center - Toledo
Toledo, Ohio
Monongahela Valley Hospital
Monongahela, Pennsylvania
Carolina Blood and Cancer Care Associates, P.A.
Rock Hill, South Carolina
The West Clinic, PC dba West Cancer Center
Germantown, Tennessee
Cheyenne Regional Medical Center
Cheyenne, Wyoming
JSC Saint Nikolozi Surgery and Oncological Centre
Kutaisi, Georgia
LTD Institute of Clinical Oncology
Tbilisi, Georgia
LTD Tbilisi Oncology Dispensary
Tbilisi, Georgia
LTD S.Khechinashvili University Hospital
Tbilisi, Georgia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.